In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Select congresses

    Select Select congresses(s)

  • Year

    Select Year(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • Select congresses
  • sub-topic
  • Year
  • Resource type
  • Topic
  • Select congresses
  • sub-topic
  • Year
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Boehringer Ingelheim

213 results for your search

10 years since RE-LY: applying innovations in anticoagulation

Congress : ESC Congress 2019

  • Session : 10 years since RE-LY: applying innovations in anticoagulation
  • Speaker : E Hylek (Boston,US), H Darius (Berlin,DE)
  • Sponsored by Boehringer Ingelheim

Advancing evidence-based care in patients with type 2 diabetes: new opportunities for cardiologists.

Congress : Heart Failure 2019

  • Session : Know it by heart - New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : R Fontes Carvalho (Porto,PT)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Antithrombotic therapy in atrial fibrillation patients post-PCI: guidance from both sides of the Atlantic

Congress : ESC Congress 2019

  • Session : Antithrombotic therapy in atrial fibrillation patients post-percutaneous coronary intervention: guidance from both sides of the Atlantic
  • Speaker : C Cannon (Boston,US), G Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Antithrombotic therapy post-PCI: is your practice keeping up with the guidelines?

Congress : ESC Congress 2019

  • Session : NOACs in patients undergoing cardiac procedures
  • Speaker : DJ Angiolillo (Jacksonville,US)
  • Sponsored by Boehringer Ingelheim

Antithrombotic therapy post-PCI: practical tips for challenging scenarios

Congress : ESC Congress 2019

  • Session : NOACs in patients undergoing cardiac procedures
  • Speaker : J ten Berg (Nieuwegein,NL)
  • Sponsored by Boehringer Ingelheim

Audience questions and answers, summary and close

Congress : ESC Congress 2019

  • Session : SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes
  • Speaker : TF Luscher (London,GB)
  • Sponsored by The Boehringer Ingelheim, Eli Lilly and Company Alliance

Cardioversion, ablation, and devices: practical tips to treat your atrial fibrillation patients

Congress : ESC Congress 2019

  • Session : NOACs in patients undergoing cardiac procedures
  • Speaker : D Gupta (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Contemporary pharmacoinvasive treatment for STEMI

Congress : ESC Congress 2019

  • Session : STEMI care today: can we do better?
  • Speaker : N Danchin (Montreuil,FR)
  • Sponsored by Boehringer Ingelheim

Evidence, guidelines, clinical practice - The evolving role of cardiologists in the SGLT2 inhibitor era

Congress : ESC Congress 2019

  • Session : Evidence, guidelines, clinical practice - The evolving role of cardiologists in the SGLT2 inhibitor era
  • Speaker : N Marx (Aachen,DE), S Anker (Berlin,DE)
  • Sponsored by The Boehringer Ingelheim and Eli Lilly and Company Alliance

From RE-LY to RE-DUAL PCI: a decade of innovation

Congress : ESC Congress 2019

  • Session : NOACs in patients undergoing cardiac procedures
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are